BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

Core Insights - BridgeBio Pharma, Inc. announced the presentation of long-term efficacy and safety data for acoramidis in patients with ATTR-CM at the ACC Annual Scientific Sessions & Expo [1] - The company will present a late-breaking oral presentation and three posters detailing additional findings from the open-label extension trial [2] Group 1: Presentation Details - The late-breaking oral presentation titled "Long-Term Survival Benefits and Disease Stabilization with Acoramidis in Patients with ATTR-CM" will be presented by Dr. Prem Soman on March 30, 2026 [2] - Three posters will cover various aspects of acoramidis treatment, including its effects on serum transthyretin concentrations and health status related to heart failure [2] Group 2: Product Information - Attruby™ (acoramidis) is indicated for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM) in adults, aiming to reduce cardiovascular death and related hospitalizations [3] Group 3: Safety Information - Adverse reactions reported for Attruby include diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo), with most being mild and resolving without discontinuation [4]